Genetically Attenuated Plasmodium berghei Liver Stages Induce Sterile Protracted Protection That Is Mediated by Major Histocompatibility Complex Class I-Dependent Interferon-γ-Producing CD8+ T Cells

At present, radiation-attenuated plasmodia sporozoites (γ-spz) is the only vaccine that induces sterile and lasting protection in malaria-naive humans and laboratory rodents. However, γ-spz are not without risks. For example, the heterogeneity of the γ-spz could explain occasional breakthrough infec...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:The Journal of infectious diseases 2007-08, Vol.196 (4), p.599-607
Hauptverfasser: Jobe, Ousman, Lumsden, Joanne, Mueller, Ann-Kristin, Williams, Jackie, Silva-Rivera, Hilda, Kappe, Stefan H. I., Schwenk, Robert J., Matuschewski, Kai, Krzych, Urszula
Format: Artikel
Sprache:eng
Schlagworte:
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
Beschreibung
Zusammenfassung:At present, radiation-attenuated plasmodia sporozoites (γ-spz) is the only vaccine that induces sterile and lasting protection in malaria-naive humans and laboratory rodents. However, γ-spz are not without risks. For example, the heterogeneity of the γ-spz could explain occasional breakthrough infections. To avoid this possibility, we constructed a double-knockout P. berghei parasite by removing 2 genes, UIS3 and UIS4, that are up-regulated in infective spz. We evaluated the double-knockout Pbuis3(-)/4(-) parasites for protective efficacy and the contribution of CD8+ T cells to protection. Pbuis3(-)/4(-) spz induced sterile andprotractedprotection in C57BL/6 mice. Protection was linked to CD8+ T cells, given that mice deficient in β2 m were not protected. Pbuis3(-)/4(-) spz-immune CD8+ T cells consisted of effector/memory phenotypes and produced interferon-γ. On the basis of these observations, we propose that the development of genetically attenuated P. falciparum parasites is warranted for tests in clinical trials as a pre-erythrocytic stage vaccine candidate.
ISSN:0022-1899
1537-6613
DOI:10.1086/519743